Competitive Strategies in the Pharmaceutical Industry
Robert B. Helms
AEI Press, 1996 - Business & Economics - 376 pages
The growth of government programs and managed care has altered how pharmaceuticals are marketed and sold in the United States. Such change has shortened the expected revenue stream from most products - even though new technologies have increased both the cost and the medical attractiveness of those products. Managers of government and private health care programs are looking for new ways to reduce the cost of drug benefits, while company R&D managers are seeking ways to speed the regulatory process and develop new markets to cover the increasing cost of research. This volume examines various aspects of the continuing policy dispute and offers several views on the future of the pharmaceutical industry.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Introduction Robert B Helms
Generics and the Producer Price Index
An Updated and Extended Study of the Price Growth
24 other sections not shown
accounting rates advertising analysis approval approved drug assets average price basic research benefits beta brand cash flows changes chemical entities clinical Cockburn coefficient comparisons competitive consumers cost of capital cost-effectiveness cost-effectiveness analysis debt ratios depreciation discount rate Divisia index dollars drug prices drug's share economic equity estimates example FDA's firm's Grabowski and Vernon Griliches important increase indication industrial policy Innovation investment journal articles Laspeyres Laspeyres index maceutical manufacturers measure ment million opportunity cost output patent expiration percent period phar pharma pharmaceutical firms pharmaceutical industry pharmaceutical market pharmaceutical R&D physicians prazosin prescription drugs present value price index Producer Price Index profits promotion quality-adjusted R&D employee R&D productivity rate of return regression regulation regulatory reported research and development risk sample seller-provided information significant Statistics studies therapeutic classes therapy tion top decile United variables Zantac Zvi Griliches